Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Kim KS, Han KA, Kim TN, Park CY, Park JH, Kim SY, Kim YH, Song KH, Kang ES, Kim CS, Koh G, Kang JG, Kim MK, Han JM, Kim NH, Mok JO, Lee JH, Lim S, Kim SS, Kim TH, Won KC, Lee KY, Cho JH, Han JY, Kim SH, Nah JJ, Song HR, Lee SE, Kim S; ENHANCE-D Investigators. Kim KS, et al. Among authors: koh g. Diabetes Metab. 2023 Jul;49(4):101440. doi: 10.1016/j.diabet.2023.101440. Epub 2023 Mar 9. Diabetes Metab. 2023. PMID: 36906135 Free article. Clinical Trial.
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
Park J, Park SW, Yoon KH, Kim SR, Ahn KJ, Lee JH, Mok JO, Chung CH, Han KA, Koh GP, Kang JG, Lee CB, Kim SH, Kwon NY, Kim DM. Park J, et al. Diabetes Obes Metab. 2017 Dec;19(12):1681-1687. doi: 10.1111/dom.12987. Epub 2017 Jul 7. Diabetes Obes Metab. 2017. PMID: 28448688 Free PMC article. Clinical Trial.
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Chon S, Rhee SY, Ahn KJ, Baik SH, Park Y, Nam MS, Lee KW, Yoo SJ, Koh G, Lee DH, Kim YS, Woo JT; KIIT study investigators. Chon S, et al. Among authors: koh g. Diabetes Obes Metab. 2018 May;20(5):1121-1130. doi: 10.1111/dom.13196. Epub 2018 Jan 22. Diabetes Obes Metab. 2018. PMID: 29272062 Clinical Trial.
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY. Kang YM, et al. Among authors: koh g. Diabetes Metab J. 2019 Aug;43(4):432-446. doi: 10.4093/dmj.2018.0092. Epub 2019 Jun 19. Diabetes Metab J. 2019. PMID: 31237133 Free PMC article. Clinical Trial.
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines.
Yun SJ, Jeong IK, Cha JH, Lee J, Cho HC, Choi SH, Chun S, Jeon HJ, Kang HC, Kim SS, Ko SH, Koh G, Kwon SK, Lee JH, Moon MK, Noh J, Park CY, Kim S. Yun SJ, et al. Among authors: koh g. Diabetes Metab J. 2021 May;46(3):464-475. doi: 10.4093/dmj.2021.0088. Epub 2022 Mar 3. Diabetes Metab J. 2021. PMID: 35235742 Free PMC article.
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Ryang S, Kim SS, Bae JC, Han JM, Kwon SK, Kim YI, Nam-Goong IS, Kim ES, Kim MK, Lee CW, Yoo S, Koh G, Kwon MJ, Park JH, Kim IJ. Ryang S, et al. Among authors: koh g. Diabetes Obes Metab. 2022 Sep;24(9):1800-1809. doi: 10.1111/dom.14766. Epub 2022 Jun 9. Diabetes Obes Metab. 2022. PMID: 35581902 Free PMC article. Clinical Trial.
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Yang YS, Min KW, Park SO, Kim KS, Yu JM, Hong EG, Cho SR, Won KC, Kim YH, Oh S, Choi SH, Koh G, Huh W, Kim SY, Park KS. Yang YS, et al. Among authors: koh g. Diabetes Obes Metab. 2023 Aug;25(8):2096-2104. doi: 10.1111/dom.15080. Epub 2023 Apr 24. Diabetes Obes Metab. 2023. PMID: 37016484 Clinical Trial.
800 results